Evidence map›Paper›PMID 35117215›Full record

ArticleTranslational cancer research2020

Association between

Lei Lei, Wen-Xian Wang, You-Cai Zhu, Xing-Xiang Pu, Yong Fang, Hong Wang, Wu Zhuang, Yin-Bin Zhang, Li-Ping Wang, Chun-Wei Xu and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Lei Lei *Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China.
Wen-Xian Wang *Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China.
You-Cai ZhuDepartment of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, China.
Xing-Xiang PuDepartment of Medical Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Yong FangDepartment of Oncology, Sir Run Run Shaw Hospital, Hangzhou, China.
Hong WangDepartment of Lung Cancer, the Fifth Medical Center, General of PLA, Beijing, China.
Wu ZhuangDepartment of Medical Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China.
Yin-Bin ZhangDepartment of Oncology, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China.
Li-Ping WangDepartment of Oncology, Baotou Cancer Hospital, Baotou, China.
Chun-Wei XuDepartment of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China.
Mei-Yu FangDepartment of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China.
Fujian Medical University · CNZhejiang Cancer Hospital · CNBaotou Medical College · CNCentral South University · CNChinese Academy of Sciences · CNChinese PLA General Hospital · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CNSir Run Run Shaw Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsKaplan-Meier survival curves were used to compare the prognostic difference of progression-free survival (PFS) and overall survival (OS) in different classes of

resultsA total of 40 stage IIIB/IV NSCLC patients with

conclusionsPemetrexed-based regimen could be considered as first-line chemotherapy in advanced NSCLC patients with

Indexed as

BRAF mutationchemotherapynon-small cell lung cancer (NSCLC)pemetrexed

Identifiers

PMID35117215
PMCPMC8798181
OpenAlexW3083086488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.